The Pharma Data
MARCH 8, 2021
Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology. coli extract-based cell-free protein expression assays.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 12, 2021
“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir.
The Pharma Data
JULY 12, 2021
“Our decades-long commitment to fighting the epidemic is stronger than ever as we continue to build on our legacy of research and innovation in HIV,” said Dr. Joan Butterton, vice president, Global Clinical Development, Infectious Diseases, Merck Research Laboratories. “We
Drug Target Review
AUGUST 28, 2024
We then incubate the cells to mature into ‘pro-regenerative’ macrophages and insert two RNA messages to produce two human proteins that will be expressed at the site of injury when these ‘engineered’ macrophages are given back to the patient. The patient’s own monocytes, a type of white blood cell, are removed via an apheresis procedure.
Codon
APRIL 2, 2023
A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Nucleic Acids Research. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q).
The Pharma Data
NOVEMBER 18, 2021
As previously reported, at 48 weeks, both trials met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels ?50 All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”.
Expert insights. Personalized for you.
69 
Let's personalize your content